GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spark Therapeutics Inc (NAS:ONCE) » Definitions » EBITDA per Share

Spark Therapeutics (Spark Therapeutics) EBITDA per Share : $-6.29 (TTM As of Sep. 2019)


View and export this data going back to 2015. Start your Free Trial

What is Spark Therapeutics EBITDA per Share?

Spark Therapeutics's EBITDA per Share for the three months ended in Sep. 2019 was $-1.71. Its EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2019 was $-6.29.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Spark Therapeutics's EBITDA per Share or its related term are showing as below:

ONCE's 3-Year EBITDA Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 6.05
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

Spark Therapeutics's EBITDA for the three months ended in Sep. 2019 was $-66.14 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.


Spark Therapeutics EBITDA per Share Historical Data

The historical data trend for Spark Therapeutics's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spark Therapeutics EBITDA per Share Chart

Spark Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
EBITDA per Share
Get a 7-Day Free Trial -1.10 -2.01 -4.23 -7.16 -5.00

Spark Therapeutics Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.34 -1.49 -1.44 -1.65 -1.71

Spark Therapeutics EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Spark Therapeutics's EBITDA per Share for the fiscal year that ended in Dec. 2018 is calculated as

EBITDA per Share(A: Dec. 2018 )
=EBITDA/Shares Outstanding (Diluted Average)
=-186.721/37.367
=-5.00

Spark Therapeutics's EBITDA per Share for the quarter that ended in Sep. 2019 is calculated as

EBITDA per Share(Q: Sep. 2019 )
=EBITDA/Shares Outstanding (Diluted Average)
=-66.137/38.748
=-1.71

EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spark Therapeutics  (NAS:ONCE) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Spark Therapeutics EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Spark Therapeutics's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Spark Therapeutics (Spark Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3737 Market Street, Suite 1300, Philadelphia, PA, USA, 19104
Spark Therapeutics Inc is a biotechnology company with a focus on gene therapy and orphan disease treatment. The company has one business segment, Pharmaceuticals, which is principally engaged in utilizing gene therapy to develop products to aid patients suffering from debilitating diseases. Spark has a pipeline with products that target choroideremia, genetic blinding conditions or inherited retinal disease, and a product targeting hematologic disorders. The company earns the vast majority of its revenue in the United States.
Executives
Elliot Sigal director
Steven Altschuler director MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026
Stephen W Webster officer: CHIEF FINANCIAL OFFICER C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel Faga officer: Chief Business Officer 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Lota S. Zoth director, officer: CHIEF SCIENTIFIC OFFICER 334 CR 692, BUFFALO GAP TX 79508
Lars Ekman director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Robert J Perez director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER ST., WALTHAM MA 02451
Anand Mehra director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Roche Holding Ltd 10 percent owner ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070
Katherine A High director, officer: See Remarks 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
John Furey officer: Chief Operating Officer 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Vivaldi Coelho Rogerio officer: Chief Commercial Officer 225 SECOND AVENUE, WALTHAM MA 02451
Srinivas Akkaraju 10 percent owner 565 EVERETT AVENUE, PALO ALTO CA 94301
Sofinnova Venture Partners Viii, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025

Spark Therapeutics (Spark Therapeutics) Headlines

From GuruFocus